The following are studies that used ADDRESS-2 to find and contact candidates:
MELD-ATG
No longer recruiting
Summary
People develop Type 1 diabetes (T1D) because their immune system, the part of the body which helps fight infection, mistakenly attacks and destroys the insulin-producing cells in the pancreas (beta cells). When the immune system destroys these cels, the body’s ability to produce insulin decreases, blood glucose levels run high, and T1D develops.
Previous research has shown that a drug called anti-thymocyte globulin (ATG) may help prevent the immune system from attacking and destroying the insulin-producing beta cells. In the MELD-ATG trial, we are looking for the minimum effective low dose of ATG in young people newly diagnosed with T1D that (1) Can slow the decline of beta cell function and preserve the body’s own insulin production and (2) has managable side effects.
IMPACT
No longer recruiting
Summary
This study aims to evaluate the effect of IMCY-0098 on the immune signature (treatment-specific biomarkers), and the effect of the study drug upon the preservation of beta-cell function in adult patients with Type 1 Diabetes. Further safety data will also be collected.
Research study for people with Type 1 Diabetes: EXALT
No longer recruiting
Summary
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes. The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
